Evidence map›Paper›PMID 32600391›Full record

ArticleAntimicrobial resistance and infection control2020

The impact of antimicrobial stewardship program implementation at four tertiary private hospitals: results of a five-years pre-post analysis.

Awad Al-Omari, Abbas Al Mutair, Saad Alhumaid, Samer Salih, Ahmed Alanazi, Hesham Albarsan, Maha Abourayan, Maha Al Subaie

Open access · goldAbstract readComparative StudyMulticenter Study
In one paragraph

Article in Antimicrobial resistance and infection control, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed, 4 pooled it
7.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 4 syntheses or guidelines pooled it, 130 citations in OpenAlex.

  1. Pooled it
  2. Efficacy of Ceftazidime-avibactam in treating Gram-negative infections: a systematic review and meta-analysis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Awad Al-OmariResearch Center, Dr Sulaiman Al Habib Medical Group, Riyadh, Saudi Arabia.
Abbas Al MutairResearch Center, Dr Sulaiman Al Habib Medical Group, Riyadh, Saudi Arabia. abbas4080@hotmail.com.ORCID 0000-0002-9471-2767
Saad AlhumaidMinistry of Health, Canberra, Australia.
Samer SalihResearch Center, Dr Sulaiman Al Habib Medical Group, Riyadh, Saudi Arabia.
Ahmed AlanaziResearch Center, Dr Sulaiman Al Habib Medical Group, Riyadh, Saudi Arabia.
Hesham AlbarsanResearch Center, Dr Sulaiman Al Habib Medical Group, Riyadh, Saudi Arabia.
Maha AbourayanResearch Center, Dr Sulaiman Al Habib Medical Group, Riyadh, Saudi Arabia.
Maha Al SubaieResearch Center, Dr Sulaiman Al Habib Medical Group, Riyadh, Saudi Arabia.
Sulaiman Al Rajhi Colleges · SAAlfaisal University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAntimicrobial stewardship (AMS) programs have shown to reduce the emergence of antimicrobial resistance (AMR) and health-care-associated infections (HAIs), and save health-care costs associated with an inappropriate antimicrobial use. The primary objective of this study was to compare the consumption and cost of antimicrobial agents using defined daily dose (DDD) and direct cost of antibiotics before and after the AMS program implementation. Secondary objective was to determine the rate of HAIs [Clostridium difficile (C. difficile), ventilator-associated pneumonia (VAP), and central line-associated bloodstream infection (CLABSI) before and after the AMS program implementation.

methodsThis is a pre-post quasi-experimental study. Adult inpatients were enrolled in a prospective fashion under the active AMS arm and compared with historical inpatients who were admitted to the same units before the AMS implementation. Study was conducted at four tertiary private hospitals located in two cities in Saudi Arabia. Adult inpatients were enrolled under the pre- AMS arm and post- AMS arm if they were on any of the ten selected restricted broad-spectrum antibiotics (imipenem/cilastatin, piperacillin/tazobactam, colistin, tigecycline, cefepime, meropenem, ciprofloxacin, moxifloxacin, teicoplanin and linezolid).

resultsA total of 409,403 subjects were recruited, 79,369 in the pre- AMS control and 330,034 in the post- AMS arm. Average DDDs consumption of all targeted broad-spectrum antimicrobials from January 2016 to June 2019 post- AMS launch was lower than the DDDs use of these agents pre- AMS (233 vs 320 DDDs per 1000 patient-days, p = 0.689). Antimicrobial expenditures decreased by 28.45% in the first year of the program and remained relatively stable in subsequent years, with overall cumulative cost savings estimated at S.R. 6,286,929 and negligible expenses of S.R. 505,115 (p = 0.648). Rates of healthcare associated infections involving C. difficile, VAP, and CLABSI all decreased significantly after AMS implementation (incidence of HAIs in 2015 compared to 2019: for C. difficile, 94 vs 13, p = 0.024; for VAP, 24 vs 6, p = 0.001; for CLABSI, 17 vs 1, p = 0.000; respectively).

conclusionImplementation of AMS program at HMG healthcare facilities resulted in reduced antimicrobials use and cost, and lowered incidence of healthcare associated infections.

Indexed as

AdultAnti-Bacterial AgentsAntimicrobial StewardshipCross InfectionDrug PrescriptionsFemaleHumansIncidenceMalePrivate SectorProspective StudiesSaudi ArabiaTertiary Care CentersAnti-Bacterial AgentsAntimicrobial agentsBroad-spectrum antibioticsConsumptionCostDefined daily doseHealthcare associated infectionsSaudi Arabia

Identifiers

PMID32600391
PMCPMC7322716
OpenAlexW3037507774

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.